Administration of Sympathomimetic Drugs with the Selective MAO-A Inhibitor Brofaromine
| Autor: | P. R. Bieck, B. Mühlbauer, K. H. Antonin, G. Gradin-Frimmer, C. H. Gleiter |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
biology
business.industry General Medicine Pharmacology Discontinuation chemistry.chemical_compound Blood pressure chemistry Anesthesia Brofaromine biology.protein Medicine Pharmacology (medical) Nasal administration Monoamine oxidase A business Phenylephrine Anorexiants Phenylpropanolamine medicine.drug |
| Zdroj: | Drug Investigation. 4:149-154 |
| ISSN: | 1179-1918 0114-2402 |
| DOI: | 10.1007/bf03258393 |
| Popis: | The interaction between the sympathomimetic agents phenylephrine and phenylpropanol-amine (as used in cold remedies or anorexiants) and the new selective and reversible MAO-A inhibitor brofaromine (Consonar®) 75mg administered twice daily for 10 days was assessed in 6 volunteers, with particular attention to the occurrence of hypertensive episodes. The recommended maximal intranasal dose of phenylephrine (2.5mg; Neo-Synephrine®) caused no clinically relevant increase in blood pressure before or during brofaromine treatment. Immediate release phenylpropanolamine (in gelatine capsules) caused a 3.3-fold increase in pressor sensitivity during brofaromine treatment. Two to 3 days after discontinuation of brofaromine treatment pressor sensitivity to immediate release phenylephrine was increased only 1.4-fold. The pressor effect of slow release phenylpropanolamine 75mg (Acutrim Late Day®) was monitored continuously for 8 hours. There was no clinically relevant increase in systolic blood pressure during combined treatment with brofaromine and slow release phenylpropanolamine. Diastolic pressure remained unchanged. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink